Sekhmet Pharmaventures has outlined a three-year plan to reach ₹2,000 crore in revenue, marking a significant expansion for the private equity-backed pharmaceutical platform.
The company, which operates through Anjan Drugs and Optimus Drugs, intends to fund the growth through internal accruals rather than external debt.
The strategy involves a capital expenditure of ₹125-150 crore, primarily directed toward adding approximately 400 kiloliters of high-compliance reactor capacity.
This investment signals a deliberate pivot away from a volume-driven active pharmaceutical ingredient (API) business model toward higher-value, compliant manufacturing.
The move aims to improve margins and reduce reliance on low-margin commodity API sales.
This expansion aligns with a broader trend among Indian mid-cap pharmaceutical and healthcare companies setting aggressive multi-year growth targets.